News Articles February 2022

Written on 04 February 2022.

Ohio State Opens New Cancer Trials

Dozens of new cancer trials are now open at the Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). If you would like more information or are interested in referring a patient to one of these trials, call The James Line at 1-800-293-5066. To search all cancer clinical trials available at the OSUCCC – James, visit cancer.osu.edu

Pituitary Journey: Diagnosing Cushing's

A column by Brandy Moody in Cushing’s Disease News recounts her six-month process, with multiple tests, an MRI and inferior petrosal sinus sampling that led to a diagnosis. Read more here:

Dr. Fred Gentili: In Memoriam

gentili The PNA would like to offer our condolences to the family and friends of Dr. Fred Gentili, a well- respected pituitary neurosurgeon in Toronto, Canada, and a longtime member of the the PNA. Dr. Gentili was a professor in the Department of Surgery at the University of Toronto. He served as the first Director of the Skull Base Centre at the University of Toronto and was a founding member of the North American Skull Base Society. Read more here:

FDA Declines to Approve Pfizer’s Once-Weekly Drug for Pediatric GH Deficiency

Reuters reports that the U.S. Food and Drug Administration has turned down Pfizer’s application to approve a once-weekly drug called Somatrogon to combat growth hormone deficiency in children. Read more here:

However the same drug was just approved in Japan. Read more here:

Hypothyroidism and Insomnia

An article in Medical News Today looks at the link between low thyroid levels and subclinical insomnia. Often doctors associate sleeplessness with over-active thyroid, but some research suggests it can occur in patients with under-active thyroid. Read more:

Oral Octreotide Found Effective Against Acromegaly For 62 Weeks

An article in Healio reports on the results of the MPOWERED trial, which found that a 26-week course of oral octreotide worked to control acromegaly in almost all people after 62 weeks. Read more: